{"id":"NCT03721172","sponsor":"Amgen","briefTitle":"Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy","officialTitle":"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-11","primaryCompletion":"2020-03-06","completion":"2020-07-24","firstPosted":"2018-10-26","resultsPosted":"2021-05-17","lastUpdate":"2024-05-29"},"enrollment":595,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Apremilast","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo-controlled Phase:","type":"EXPERIMENTAL"},{"label":"Placebo-controlled Phase: Apremilast 30 mg","type":"EXPERIMENTAL"},{"label":"Extension Phase: Apremilast 30 mg","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.\n\nApproximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.","primaryOutcome":{"measure":"Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase","timeFrame":"Baseline and Week 16 of the placebo-controlled phase","effectByArm":[{"arm":"Placebo-controlled Phase: Placebo","deltaMin":4.1,"sd":null},{"arm":"Placebo-controlled Phase: Apremilast 30 mg","deltaMin":21.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":64,"countries":["United States","Canada"]},"refs":{"pmids":["34343599","37316690"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":296},"commonTop":["Diarrhoea","Headache","Nausea","Upper respiratory tract infection","Nasopharyngitis"]}}